TRIM13 in situ engineering boosts anti-inflammatory capacity of CAR-Ms for liver fibrosis therapy
✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source
Researchers have made a development in liver fibrosis therapy using CAR-Ms. The approach involves in situ engineering of TRIM13, which appears to enhance the anti-inflammatory capacity of CAR-Ms. This development may have implications for the treatment of liver fibrosis.